Healthtech startup Respiree has secured approval from Singapore’s Health Sciences Authority (HSA) for its AI-enabled 1BioAI software, designed to assist healthcare professionals in detecting acute inpatient deterioration. The 1BioAI Acute toolbox, classified as a Class B software-as-a-medical device, utilises machine learning models to enhance precision in identifying patient deterioration, thereby reducing false alerts and improving clinical support.
The 1BioAI Acute system operates by analysing bedside-recorded vital signs—pulse rate, respiratory rate, oxygen saturation, and systolic blood pressure—to generate a probability score. This score helps clinicians assess whether additional monitoring is necessary, indicating the patient’s general physiological state. “Advanced AI-driven machine learning models have the potential to deliver significantly greater precision, reducing unnecessary alerts,” said Dr Gurpreet Singh, CEO and Founder of Respiree.
The approval marks a significant milestone for Respiree, whose 1Bio platform and RS001 wearable device have also received regulatory clearance. With this achievement, Respiree plans to expand regulatory approvals for the 1BioAI Acute toolbox across other Asia-Pacific (APAC) and Australia-New Zealand (ANZ) regions, as well as in the United States in the coming months.
The HSA’s approval follows a validation study published in the Mayo Clinic Proceedings, further establishing the credibility of Respiree’s technology. As the company looks to broaden its reach, the potential for improved patient care through AI-driven precision continues to grow.
